Levett Jeremy Y, Raparelli Valeria, Mardigyan Vartan, Eisenberg Mark J
Center of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, Quebec, Canada.
Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
CJC Open. 2020 Sep 5;3(1):28-40. doi: 10.1016/j.cjco.2020.09.003. eCollection 2021 Jan.
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly evolving, with important cardiovascular considerations. The presence of underlying cardiovascular risk factors and established cardiovascular disease (CVD) may affect the severity and clinical management of patients with COVID-19. We conducted a review of the literature to summarize the cardiovascular pathophysiology, risk factors, clinical presentations, and treatment considerations of COVID-19 patients with underlying CVD. Angiotensin-converting enzyme 2 (ACE2) has been identified as a functional receptor for the SARS-CoV-2 virus, and it is associated with the cardiovascular system. Hypertension, diabetes, and CVD are the most common comorbidities in COVID-19 patients, and these factors have been associated with the progression and severity of COVID-19. However, elderly populations, who develop more-severe COVID-19 complications, are naturally exposed to these comorbidities, underscoring the possible confounding of age. Observational data support international cardiovascular societies' recommendations to not discontinue ACE inhibitor/angiotensin-receptor blocker therapy in patients with guideline indications for fear of the increased risk of SARS-CoV-2 infection, severe disease, or death. In addition to the cardiotoxicity of experimental antivirals and potential interactions of experimental therapies with cardiovascular drugs, several strategies for cardiovascular protection have been recommended in COVID-19 patients with underlying CVD. Troponin elevation is associated with increased risk of in-hospital mortality and adverse outcomes in patients with COVID-19. Cardiovascular care teams should have a high index of suspicion for fulminant myocarditis-like presentations being SARS-CoV-2 positive, and remain vigilant for cardiovascular complications in COVID-19 patients.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)大流行正在迅速演变,存在重要的心血管方面的考量。潜在心血管危险因素和已确诊心血管疾病(CVD)的存在可能会影响COVID-19患者的病情严重程度和临床管理。我们对文献进行了综述,以总结合并CVD的COVID-19患者的心血管病理生理学、危险因素、临床表现及治疗考量。血管紧张素转换酶2(ACE2)已被确定为SARS-CoV-2病毒的功能性受体,且与心血管系统相关。高血压、糖尿病和CVD是COVID-19患者最常见的合并症,这些因素与COVID-19的进展和严重程度相关。然而,发生更严重COVID-19并发症的老年人群自然也存在这些合并症,这凸显了年龄可能产生的混杂影响。观察性数据支持国际心血管学会的建议,即对于有指南适应证的患者,不要因担心SARS-CoV-2感染、重症或死亡风险增加而停用ACE抑制剂/血管紧张素受体阻滞剂治疗。除了实验性抗病毒药物的心脏毒性以及实验性疗法与心血管药物的潜在相互作用外,对于合并CVD的COVID-19患者,还推荐了几种心血管保护策略。肌钙蛋白升高与COVID-19患者住院死亡率和不良结局风险增加相关。心血管护理团队应对呈SARS-CoV-2阳性的暴发性心肌炎样表现保持高度怀疑,并对COVID-19患者的心血管并发症保持警惕。